|
| Press Releases |
|
 |
|
| Friday, October 30, 2020 |
|
|
Avance Clinical Wins MasterControl 2020 Innovation Excellence Award |
| The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony. more info >> |
|
| Wednesday, October 28, 2020 |
|
|
Biotechs get scalable early to late phase clinical offering from Avance Clinical and Cromos Pharma - announced at Bio-Europe 2020 |
| Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs. more info >> |
|
| Tuesday, September 22, 2020 |
|
|
Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America |
| The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis. www.avancecro.com/eclinical-solutions more info >> |
|
| Friday, September 4, 2020 |
|
|
Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company's phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn's disease. more info >> |
|
| Wednesday, July 22, 2020 |
|
|
Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics' proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa's proprietary Endoxifen. more info >> |
|
| Thursday, July 9, 2020 |
|
|
Avance Clinical Wins Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award |
| The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight. more info >> |
|
| Tuesday, June 9, 2020 |
|
|
TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020 |
| The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing. more info >> |
|
| Thursday, April 9, 2020 |
|
|
Australian CRO Avance Clinical Designated an Essential Service as Strong Demand from Sponsors Continues Amid COVID-19 Crisis |
| Leading Australian CRO Avance Clinical said there was still strong demand from Asian and US sponsors, and commended Australian sites that had risen to the challenge to deliver for Avance Clinical clients during this difficult time. more info >> |
|
| Thursday, April 2, 2020 |
|
|
Avance Clinical on Top Reasons APAC Biotech Clients Choose Australia for Clinical Trials |
| Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. more info >> |
|
| Friday, March 20, 2020 |
|
|
Australian CRO, Avance Clinical is Uniquely Positioned for COVID-19 Vaccines and Therapies Clinical Trials |
| Australian CRO Avance Clinical said today that Australia's fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites, as well as the attractive 40% Government rebate on clinical trial spend, means Avance is uniquely positioned to deliver rapid results for urgent COVID-19 trials. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Military Metals Appoints DGWA as European Financial Markets Advisor
Feb 5, 2025 21:39 HKT/SGT
|
|
|
Doubleview Gold Corp Increases the Dimensions of the Hat Polymetallic Deposit with High-Grade and Extensive Mineralization in Drill Holes H075 to H077
Feb 5, 2025 18:59 HKT/SGT
|
|
|
Approval in Principle (AiP) Acquired from Classification Society for Low-Pressure Type Coastal Liquefied CO2 Carrier 
Feb 5, 2025 17:46 JST
|
|
|
Toyota Powers On New North Carolina Automotive Battery Plant
Feb 5, 2025 13:59 JST
|
|
|
Toyota to Form Comprehensive Partnership on Carbon Neutrality with Shanghai and Establish a Company to Develop and Produce BEVs and Batteries
Feb 5, 2025 13:56 JST
|
|
|
Fujitsu to highlight AI-powered network technologies at MWC Barcelona 2025
Feb 5, 2025 10:25 JST
|
|
|
QSEC-CEE 2025 Concludes with Breakthroughs in Quantum Cybersecurity
Feb 4, 2025 20:00 HKT/SGT
|
|
|
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
Feb 4, 2025 18:00 HKT/SGT
|
|
|
TOYOTA GAZOO Racing Launches Evolved GR Corolla in Japan
Feb 4, 2025 18:41 JST
|
|
|
Mitsubishi Heavy Industries Achieves Double-Digit Order Intake and Profit Growth in First Three Quarters, Raises Full-Year Guidance
Feb 4, 2025 18:34 JST
|
|
|
MAZDA TRANS AOYAMA Opens in Minami-Aoyama
Feb 4, 2025 17:38 JST
|
|
|
Fujitsu launches gen AI software analysis and visualization service to support optimal modernization planning
Feb 4, 2025 11:39 JST
|
|
|
CyberX Summit & Awards 2025: Qatar Edition to Gather Top Cybersecurity Experts
Feb 4, 2025 09:07 HKT/SGT
|
|
|
Renewable Energy Power Purchase Agreements: Analyzing, Structuring, and Negotiating for Bankable Green Investments in Competitive Markets
Feb 4, 2025 09:00 HKT/SGT
|
|
|
Arctic Wolf and BlackBerry Announce Closing of Acquisition for Cylance
Feb 4, 2025 08:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
